This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by DeJesus, E.
Right arrow Articles by Shelton, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by DeJesus, E.
Right arrow Articles by Shelton, M. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2006, p. 3157-3159, Vol. 50, No. 9
0066-4804/06/$08.00+0     doi:10.1128/AAC.00093-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Interaction between Fosamprenavir, with and without Ritonavir, and Nevirapine in Human Immunodeficiency Virus-Infected Subjects

Edwin DeJesus,1 Peter J. Piliero,2 Kim Summers,3 Mary Beth Wire,4 Daniel S. Stein,5 Amanda Masterman,6 Yu Lou,4 Sherene S. Min,4 and Mark J. Shelton4*

Orlando Immunology Center, Orlando, Florida,1 Boehringer Ingelheim, Ridgefield, Connecticut,2 San Antonio VA, San Antonio, Texas,3 GlaxoSmithKline, Research Triangle Park, North Carolina,4 Sanofi-Aventis, Bridgewater, New Jersey,5 GlaxoSmithKline, Mississauga, Ontario, Canada6

Received 23 January 2006/ Returned for modification 15 May 2006/ Accepted 11 June 2006

Fosamprenavir (FPV) with and without ritonavir (RTV) was added to the antiretroviral regimens of human immunodeficiency virus-infected subjects receiving nevirapine (NVP) to evaluate this drug interaction. Significant reductions in plasma amprenavir exposure (25 to 35%) were observed following coadministration of 1,400 mg of FPV twice a day (BID) and 200 mg of NVP BID. A regimen of 700 mg of FPV BID plus 100 mg of RTV BID may be coadministered with NVP without dose adjustment.

* Corresponding author. Mailing address: GlaxoSmithKline, Five Moore Drive, Research Triangle Park, NC 27709. Phone: (919) 483-5062. Fax: (919) 315-4276. E-mail: Mark.J.Shelton{at}GSK.com.

Antimicrobial Agents and Chemotherapy, September 2006, p. 3157-3159, Vol. 50, No. 9
0066-4804/06/$08.00+0     doi:10.1128/AAC.00093-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»